The phase Ib KEYNOTE-028 (8) and the phase II Kelly (112) trials, conducted with pembrolizumab (PD1 inhibitor), enrolled heavily pre-treated ER+, HER2- advanced breast cancer patients selected or not for PD-L1+ tumours, respectively. The gene discussed is ESR1; the disease is breast carcinoma.